tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksChatGPT StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksTipRanks CommunityContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsSmart PortfolioExpert CenterTipRanksAI
TOOLS
My Portfolio
My Watchlist
Earnings Calendar
Stock Screener
Penny Stocks
Top Stocks
Daily Analyst Ratings
STOCKS
BABA
AAPL
SPY
AMZN
QQQ
TSLA
NVDA
ADVANCED RESEARCH
TipRanks Premium
Invest Like a Pro with Unique Data & Simplifed ToolsTry Now
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
ChatGPT Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
TipRanks Community
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

IKT Stock Latest News

Inhibikase Therapeutics files to sell common stock, warrants, no amount given
The FlyInhibikase Therapeutics files to sell common stock, warrants, no amount given
6d ago
IKT
Inhibikase Therapeutics Updates Shareholders on Future Plans
PremiumCompany Announcements
Inhibikase Therapeutics Updates Shareholders on Future Plans
7d ago
8K
IKT
Inhibikase Therapeutics provides update on development programs
PremiumThe Fly
Inhibikase Therapeutics provides update on development programs
8d ago
IKT
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
PremiumPress Releases
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
8d ago
IKT
Inhibikase Therapeutics announces pre-IND meeting with FDA for IkT-001Pro
PremiumThe Fly
Inhibikase Therapeutics announces pre-IND meeting with FDA for IkT-001Pro
23d ago
IKT
Inhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
PremiumPress ReleasesInhibikase Therapeutics Announces Pre-IND Meeting with the FDA for IkT-001Pro in Pulmonary Arterial Hypertension
23d ago
IKT
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
PremiumPress Releases
Inhibikase Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Activity
30d ago
IKT
Inhibikase Therapeutics, Inc. (IKT) Q4 Earnings Cheat Sheet
PremiumPre-Earnings
Inhibikase Therapeutics, Inc. (IKT) Q4 Earnings Cheat Sheet
1M ago
IKT
Inhibikase Therapeutics to provide trial update for Risvodetinib
PremiumThe Fly
Inhibikase Therapeutics to provide trial update for Risvodetinib
2M ago
IKT
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
PremiumPress Releases
Inhibikase Therapeutics to Provide Trial Update for Risvodetinib at the 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
2M ago
IKT
Inhibikase Therapeutics announces outcomes of pre-NDA meeting with FDA
PremiumThe Fly
Inhibikase Therapeutics announces outcomes of pre-NDA meeting with FDA
2M ago
IKT
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
PremiumPress Releases
Inhibikase Therapeutics Announces Full Outcomes of its Pre-NDA Meeting with the FDA for IkT-001Pro
2M ago
IKT
Inhibikase Discusses FDA Pathway for New Cancer Drug
PremiumCompany AnnouncementsInhibikase Discusses FDA Pathway for New Cancer Drug
3M ago
8K
IKT
Inhibikase Therapeutics announces outcomes of pre-NDA meeting with FDA
PremiumThe Fly
Inhibikase Therapeutics announces outcomes of pre-NDA meeting with FDA
3M ago
IKT
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
PremiumPress Releases
Inhibikase Therapeutics Announces Preliminary Outcomes of its Pre-NDA Meeting with the FDA on the Pathway for Approval for IkT-001Pro in Blood and Gastrointestinal Cancers
3M ago
IKT
Inhibikase Therapeutics Signs Key Stock Sale Agreement
PremiumCompany Announcements
Inhibikase Therapeutics Signs Key Stock Sale Agreement
3M ago
8K
IKT
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
PremiumPress Releases
Inhibikase Therapeutics Announces Publication Highlighting Results from its Phase 1 Studies with Risvodetinib
3M ago
IKT
Inhibikase announces publication Phase 1 studies with risvodetinib
PremiumThe Fly
Inhibikase announces publication Phase 1 studies with risvodetinib
3M ago
IKT
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
PremiumPress Releases
Inhibikase Therapeutics Announces Planned Retirement of Chief Financial Officer Joseph Frattaroli
3M ago
IKT
Inhibikase Therapeutics CFO Frattaroli to retire at Q1-end, Lees-Rolfe succeeds
PremiumThe FlyInhibikase Therapeutics CFO Frattaroli to retire at Q1-end, Lees-Rolfe succeeds
3M ago
IKT
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
PremiumPress Releases
Inhibikase Therapeutics Issues Letter to Shareholders and Provides Update on Development Programs
4M ago
IKT
Inhibikase Therapeutics issues letter to shareholders, provides update
PremiumThe Fly
Inhibikase Therapeutics issues letter to shareholders, provides update
4M ago
IKT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >